

# Jean-Baptiste Micol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628638/publications.pdf>

Version: 2024-02-01

58  
papers

2,945  
citations

279487

23  
h-index

174990

52  
g-index

59  
all docs

59  
docs citations

59  
times ranked

5972  
citing authors

#	ARTICLE	IF	CITATIONS
1	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. <i>Cancer Cell</i> , 2015, 27, 617-630.	7.7	449
2	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
3	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	15.2	301
4	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	15.2	297
5	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2451-2459.	0.6	198
6	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015, 125, 1857-1872.	3.9	151
7	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. <i>Nature</i> , 2019, 574, 273-277.	13.7	149
8	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	5.7	98
9	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	3.3	97
10	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 673-673.	0.6	66
11	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	2.5	56
12	Outcome of older patients with acute myeloid leukemia in first relapse. <i>American Journal of Hematology</i> , 2013, 88, 758-764.	2.0	49
13	The Role of Additional Sex Combs-Like Proteins in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026526.	2.9	48
14	Clinical Features and Outcomes in Patients With Disseminated Toxoplasmosis Admitted to Intensive Care: A Multicenter Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1535-1541.	2.9	47
15	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717.	1.7	41
16	EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D <sub>3</sub> in acute myeloid leukemia cells. <i>Cell Cycle</i> , 2013, 12, 2978-2991.	1.3	39
17	Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. <i>Haematologica</i> , 2014, 99, 201-203.	1.7	39
18	Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. <i>Gut Microbes</i> , 2020, 12, 1800897.	4.3	38

#	ARTICLE	IF	CITATIONS
19	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. <i>Blood</i> , 2014, 124, 3734-3734.	0.6	38
20	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i>-mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	0.6	36
21	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	0.6	28
22	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021, 153, 123-132.	1.3	25
23	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. <i>Leukemia Research</i> , 2015, 39, 818-821.	0.4	24
24	Unlike <i>ASXL1</i> and <i>ASXL2</i> mutations, <i>ASXL3</i> mutations are rare events in acute myeloid leukemia with t(8;21). <i>Leukemia and Lymphoma</i> , 2016, 57, 199-200.	0.6	19
25	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. <i>Leukemia</i> , 2018, 32, 2008-2081.	3.3	18
26	AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model. <i>Blood</i> , 2014, 124, 3735-3735.	0.6	18
27	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. <i>American Journal of Hematology</i> , 2015, 90, 859-863.	2.0	17
28	An 18-case outbreak of drug-resistant <i>Pseudomonas aeruginosa</i> bacteremia in hematology patients. <i>Haematologica</i> , 2006, 91, 1134-8.	1.7	16
29	Risk factors, clinical features, and outcome of <i>Pseudomonas aeruginosa</i> bacteremia in patients with hematologic malignancies: A case-control study. <i>American Journal of Infection Control</i> , 2013, 41, 527-530.	1.1	13
30	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Cancer Discovery</i> , 2020, 10, 1894-1911.	7.7	13
31	Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. <i>Journal of Medical Microbiology</i> , 2015, 64, 676-681.	0.7	13
32	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	2.5	12
33	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2481-2484.	0.6	11
34	Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. <i>Annals of Hematology</i> , 2006, 85, 711-716.	0.8	11
35	Invasive cutaneous infection due to <i>Scopulariopsis brevicaulis</i> unsuccessfully treated with high-dose micafungin in a neutropenic patient. <i>Infection</i> , 2017, 45, 361-363.	2.3	10
36	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 126-137.	3.3	10

#	ARTICLE	IF	CITATIONS
37	Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.. <i>Blood</i> , 2010, 116, 1083-1083.	0.6	8
38	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
39	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1742-1745.	0.6	6
40	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. <i>Blood</i> , 2016, 128, 961-961.	0.6	6
41	<i>ATG2B/GSKIP</i> in <i>de novo</i> acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1770-1773.	0.6	5
42	CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1,) Tj ETQq0 0 0 rgBT /Overlock 10 Cohort. <i>Blood</i> , 2019, 134, 1355-1355.	0.6	5
43	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. <i>Blood</i> , 2019, 134, 1416-1416.	0.6	5
44	Bone marrow metastases mimicking acute leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 556-556.	1.2	4
45	Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis. <i>Blood</i> , 2015, 126, 4-4.	0.6	4
46	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 421-428.	0.4	3
47	Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e986-e989.	0.2	3
48	Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma. <i>Blood</i> , 2015, 126, 3835-3835.	0.6	3
49	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	0.6	3
50	Myeloid malignancies with translocation t(4;12)(q11;q13;p13): molecular landscape, clonal hierarchy and clinical outcomes. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9557-9566.	1.6	2
51	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. <i>Blood</i> , 2018, 132, 993-993.	0.6	2
52	SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference. <i>Blood</i> , 2014, 124, 824-824.	0.6	2
53	ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis. <i>Blood</i> , 2015, 126, 302-302.	0.6	2
54	Spontaneous molecular response of IDH2 acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 353-354.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. <i>Blood</i> , 2019, 134, 3722-3722.	0.6	1
56	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , 2012, 120, 890-890.	0.6	1
57	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. <i>Blood</i> , 2013, 122, 1512-1512.	0.6	1
58	SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS. <i>Blood</i> , 2014, 124, 525-525.	0.6	0